# Maria Cho

> Maria Cho is a biotech executive, startup co-founder and strategic board advisor. She led Triplebar from 2022 until March 2025, overseeing commercial partnerships and a funding round completed at $21 million in 2024. Her career includes research, commercial development at WuXi AppTec and Fujifilm Diosynth Biotechnologies, and co-founding Phi Therapeutics. She writes about leadership and business execution.

- **Role:** Strategic Board Advisor to biotech startups (organizations not publicly named in her current biography)
- **Organizations:** Triplebar (former CEO), Phi Therapeutics (co-founder and former COO), FUJIFILM Diosynth Biotechnologies (former commercial leader), WuXi AppTec (former commercial and project roles), Thomas Jefferson University (former researcher), Entrepreneur (contributor)
- **Education:** University of Florida, Master’s in Biomedical Chemistry, as described in her interview, Thomas Jefferson University
- **Known for:** Co-founded Phi Therapeutics., Led Triplebar from 2022 until March 2025., Completed Triplebar’s $21 million funding round in 2024, according to the company.

## Career timeline

- **2000-2005** — Worked in sales at Vector Marketing, according to her public career listing.
- **2004-2006** — Research roles at Thomas Jefferson University, according to her public career listing.
- **2006-2012** — Project management and commercial roles at WuXi AppTec, according to her public career listing.
- **2012-2019** — Commercial development roles at FUJIFILM Diosynth Biotechnologies, eventually leading US sales.
- **2019** — Co-founded Phi Therapeutics and served as COO.
- **2022** — Became CEO of Triplebar.
- **2023** — Triplebar announced collaborations with FrieslandCampina Ingredients and Umami Meats, and a $20 million financing round.
- **2024** — Completed Triplebar’s funding round at $21 million, as stated in its 2025 succession announcement.
- **2024-09** — Announced a strategic focus on generative AI genomic language models at Triplebar.
- **2025-03** — Succeeded as Triplebar CEO by Shawn Manchester, effective March 20.
- **2025** — Published leadership and decision-making essays; current author biography identifies her as a biotech board advisor.

## Achievements

- Co-founded Phi Therapeutics.
- Led Triplebar from 2022 until March 2025.
- Completed Triplebar’s $21 million funding round in 2024, according to the company.
- Led Triplebar during announced partnerships with FrieslandCampina Ingredients and Umami Meats.
- Named as a CES 2024 food technology panel speaker.
- A 2023 Bisnow speaker biography credited her with more than $1 billion in lifetime sales.

## Latest updates

- **2025-08** — Published an essay on decision-making in Entrepreneur on August 5.
- **2025-05** — Published an essay on leadership principles in Entrepreneur on May 2.
- **2025-03** — Triplebar announced Shawn Manchester as her successor on March 20.

## Links

- LinkedIn: https://www.linkedin.com/in/mariascho/

---

Profile page: https://yespress.io/maria-cho
Published by YesPress — https://yespress.io
Last updated: 2026-10-12